STAT+: AstraZeneca strikes drug pricing deal with Trump
WASHINGTON — President Trump on Friday said he struck a drug pricing deal with AstraZeneca aimed at fulfilling his plan to bring U.S. drug prices in line with what other countries pay, the second agreement after Pfizer’s last week.
Similar to Pfizer’s deal, the British pharma company agreed to give the U.S. Medicaid program drug prices that are in line with what it offers other major developed countries and to launch new drugs at so-called “most-favored nations” prices.
In exchange, the U.S. will give the company a three-year reprieve on national security-related pharmaceutical tariffs, allowing AstraZeneca time to make all of the medicines it sells in the U.S. in this country, the company said.
Daniel Payne and Elaine Chen
Go to statnews